Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman.
Chanticleer
Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman.
Copy link
Copied
Copy link
‘Collision with reality’: The $100 billion downfall of an Aussie giant
Chutes & Ladders—Alignment Healthcare shuffles leadership team; Highmark hires former Optum CEO
Biopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?
There is no hiding from the bloody mess at CSL, one of Australia’s global success stories. Can it recover?
Naylor himself does not have his hat in the ring for the permanent CEO role but is tipped to succeed McNamee as CSL’s chairman…
Also: All the news and watercooler chat from Fortune.
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.
Also: All the news and watercooler chat from Fortune.
